# Alzheimer’s brain decline slashed in half by ‘thrilling’ new twice-a-year drug: trial

- URL: https://talkfuse.com/story/alzheimers-brain-decline-slashed-in-half-by-thrilling-new-twice-a-year-drug-trial/
- Published: 2026-11-19T17:41:26+00:00
- Updated: 2026-11-19T18:41:09+00:00
- Original publisher: New York Post (publisher lean: Right)
- Original article: https://nypost.com/2026/11/19/health/alzheimers-brain-decline-slashed-in-half-by-thrilling-new-drug-trial/
- Topics: Health, Medicine, World

## Key points

- Low-dose diranersen was linked to 54% less cognitive decline over nearly two years.
- The trial also found a reduction in aggregated tau.
- Phase 3 testing is needed to confirm the findings.

## Summary

In a Phase 2 trial, people given low-dose diranersen had 54% less decline in memory and thinking over nearly two years. The experimental drug also reduced aggregated tau, a protein associated with Alzheimer’s-related brain cell damage, raising hopes that it could slow disease progression.

Diranersen is given by injection twice a year and uses gene-silencing technology to reduce the RNA messages that prompt brain cells to produce tau. Researchers said treatment was generally well tolerated, though side effects included lumbar-puncture pain, headaches and confusion, especially at higher doses. A larger Phase 3 trial is needed to confirm the results, and recruitment in the UK is expected to begin in spring.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
